ArticleAnalytical chemistry2026
Fluorescence-Enhanced Immunoassay (FEIA) Platform by Combining AIE Nanobeads on a Plasmonic Device for Selective Detection of IL-6 Cytokine.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of advanced diagnostic systems with exceptional sensitivity and precision is important for the accurate and timely detection of biomarkers associated with inflammatory responses and autoimmune disorders. Here, we introduce a simple and high-throughput fluorescence-enhanced immunoassay (FEIA) platform for detection of cytokine interleukin (IL-6). This platform is based on a plasmonic gold substrate integrated with aggregation-induced emission (AIE) nanobeads. The plasmonic substrate is low-cost and easily scalable and can be fabricated using a straightforward plasma etching method. Our FEIA platform facilitates precise quantification of IL-6, achieving a low detection limit of 0.5 pM and a dynamic linear range from 0 to 1250 pM, manifesting the efficiency of the technique. The platform with improved fluorescence and stability of the AIE nanobeads, together with the plasmonic substrate, offers an effective tool for cytokine monitoring. By enabling easy integration into the current clinical diagnosis routine by the possible use of plate imagers and plate readers, it provides significant advancement in accuracy and diagnosis along with therapeutic outcomes for inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.